Arterial stiffness is a type of cardiovascular disorder that occurs due to arteriosclerosis and aging. Stiffness can be defined as the viscoelastic property that anticipate the relationship between change in volume and change in pressure. Due to decrease in capacity of reservoir and recoiling elasticity, the diastolic pressure decreases and pulse pressure increases. Lower diastolic pressure can increase the risk of renal impairment and stroke. However, it also reduces coronary artery perfusion leading to subendocardial ischemia. Arterial stiffness can be diagnosed by doppler analysis. Omeros Corporation is in the process of developing GPR25 as a G protein-coupled receptor agonist for the treatment of arterial stiffness. NattoPharma ASA is in the process of developing menaquinone-7 for the treatment of arterial stiffness. Some of the companies having the pipeline of arterial stiffness include Omeros Corporation, NattoPharma ASA and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.